Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target entry represents a functional grouping of the Major Histocompatibility Complex Class I-Related Protein (MR1) and the broad class of enzymes that require pyridoxine (Vitamin B6) derivatives as cofactors. MR1 is a non-polymorphic antigen-presenting molecule that captures small molecule metabolites, primarily derived from microbial riboflavin (Vitamin B2) synthesis, and presents them to Mucosal-Associated Invariant T (MAIT) cells to initiate an immune response against pathogens like Mycobacterium tuberculosis (Keller et al., 2014, Nature). Pyridoxine-dependent enzymes, such as aromatic L-amino acid decarboxylase and cystathionine beta-synthase, are essential for neurotransmitter synthesis and amino acid metabolism. The intersection of these two entities is clinically significant because several drugs, most notably the anti-tuberculosis medication isoniazid, act as antagonists to pyridoxine-dependent enzymes, leading to side effects like peripheral neuropathy, while also potentially modulating the MR1-MAIT cell axis (Keller et al., 2012, Science). This grouping is often used in the context of drug-induced metabolic interference and immunomodulation during the treatment of infectious diseases.
MR1 presents microbial vitamin B2-derived metabolites to MAIT cells to trigger immune responses; pyridoxine-dependent enzymes utilize PLP as a cofactor for various metabolic reactions, and certain drugs inhibit these enzymes or deplete PLP levels.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major histocompatibility complex class I-related protein (MR1) and pyridoxine-dependent enzymes (MR1/PLP-dependent enzymes).